{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,2,26]],"date-time":"2026-02-26T18:43:50Z","timestamp":1772131430276,"version":"3.50.1"},"reference-count":54,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2026,2,1]],"date-time":"2026-02-01T00:00:00Z","timestamp":1769904000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"},{"start":{"date-parts":[[2025,11,18]],"date-time":"2025-11-18T00:00:00Z","timestamp":1763424000000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Journal of Affective Disorders"],"published-print":{"date-parts":[[2026,2]]},"DOI":"10.1016\/j.jad.2025.120732","type":"journal-article","created":{"date-parts":[[2025,11,20]],"date-time":"2025-11-20T13:46:37Z","timestamp":1763646397000},"page":"120732","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":1,"special_numbering":"PA","title":["Does number of dosing sessions and type of adjunctive psychotherapy affect outcomes in psychedelic-assisted-psychotherapy for depressive disorders and anxiety disorders? A systematic review and meta-analysis"],"prefix":"10.1016","volume":"395","author":[{"given":"Tomas","family":"Lindegaard","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Anton","family":"K\u00e4ll","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.jad.2025.120732_bb0005","doi-asserted-by":"crossref","first-page":"555","DOI":"10.1001\/jamapsychiatry.2023.4685","article-title":"Single-dose synthetic psilocybin with psychotherapy for treatment-resistant bipolar type II major depressive episodes: a nonrandomized open-label trial","volume":"81","author":"Aaronson","year":"2024","journal-title":"JAMA Psychiatr."},{"key":"10.1016\/j.jad.2025.120732_bb0010","doi-asserted-by":"crossref","first-page":"155","DOI":"10.1177\/0269881119897615","article-title":"Long-term follow-up of psilocybin-assisted psychotherapy for psychiatric and existential distress in patients with life-threatening cancer","volume":"34","author":"Agin-Liebes","year":"2020","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2025.120732_bb0015","author":"American Psychological Association"},{"key":"10.1016\/j.jad.2025.120732_bb0020","series-title":"Introduction to Meta-Analysis","author":"Borenstein","year":"2009"},{"key":"10.1016\/j.jad.2025.120732_bb0025","doi-asserted-by":"crossref","first-page":"619","DOI":"10.1016\/S2215-0366(16)30065-7","article-title":"Psilocybin with psychological support for treatment-resistant depression: an open-label feasibility study","volume":"3","author":"Carhart-Harris","year":"2016","journal-title":"Lancet Psychiatry"},{"key":"10.1016\/j.jad.2025.120732_bb0030","doi-asserted-by":"crossref","first-page":"399","DOI":"10.1007\/s00213-017-4771-x","article-title":"Psilocybin with psychological support for treatment-resistant depression: six-month follow-up","volume":"235","author":"Carhart-Harris","year":"2018","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.120732_bb0035","doi-asserted-by":"crossref","first-page":"1402","DOI":"10.1056\/NEJMoa2032994","article-title":"Trial of psilocybin versus escitalopram for depression","volume":"384","author":"Carhart-Harris","year":"2021","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2025.120732_bb0040","article-title":"The association between diverse psychological protocols and the efficacy of psilocybin-assisted therapy for clinical depressive symptoms: a Bayesian meta-analysis","volume":"15","author":"Chen","year":"2024","journal-title":"Front. Psych."},{"key":"10.1016\/j.jad.2025.120732_bb0045","doi-asserted-by":"crossref","first-page":"481","DOI":"10.1001\/jamapsychiatry.2020.3285","article-title":"Effects of psilocybin-assisted therapy on major depressive disorder: a randomized clinical trial","volume":"78","author":"Davis","year":"2021","journal-title":"JAMA Psychiatry"},{"key":"10.1016\/j.jad.2025.120732_bb0050","doi-asserted-by":"crossref","first-page":"381","DOI":"10.1016\/j.jad.2024.09.133","article-title":"Single-dose psilocybin for US military veterans with severe treatment-resistant depression\u2013a first-in-kind open-label pilot study","volume":"369","author":"Ellis","year":"2025","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120732_bb0055","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/NMD.0000000000000113","article-title":"Safety and efficacy of lysergic acid diethylamide-assisted psychotherapy for anxiety associated with life-threatening diseases","volume":"202","author":"Gasser","year":"2014","journal-title":"J. Nerv. Ment."},{"key":"10.1016\/j.jad.2025.120732_bb0060","doi-asserted-by":"crossref","first-page":"890","DOI":"10.1007\/s11013-021-09749-y","article-title":"Ancient roots of today\u2019s emerging renaissance in psychedelic medicine","volume":"46","author":"George","year":"2022","journal-title":"Cult. Med. Psychiatry"},{"key":"10.1016\/j.jad.2025.120732_bb0065","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1056\/NEJMoa2206443","article-title":"Single-dose psilocybin for a treatment-resistant episode of major depression","volume":"387","author":"Goodwin","year":"2022","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.jad.2025.120732_bb0070","doi-asserted-by":"crossref","first-page":"1492","DOI":"10.1038\/s41386-023-01648-7","article-title":"Psilocybin for treatment resistant depression in patients taking a concomitant SSRI medication","volume":"48","author":"Goodwin","year":"2023","journal-title":"Neuropsychopharmacology"},{"key":"10.1016\/j.jad.2025.120732_bb0075","doi-asserted-by":"crossref","first-page":"1181","DOI":"10.1177\/0269881116675513","article-title":"Psilocybin produces substantial and sustained decreases in depression and anxiety in patients with life-threatening cancer: a randomized double-blind trial","volume":"30","author":"Griffiths","year":"2016","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2025.120732_bb0080","doi-asserted-by":"crossref","first-page":"71","DOI":"10.1001\/archgenpsychiatry.2010.116","article-title":"Pilot study of psilocybin treatment for anxiety in patients with advanced-stage cancer","volume":"68","author":"Grob","year":"2011","journal-title":"Arch. Gen. Psychiatry"},{"key":"10.1016\/j.jad.2025.120732_bb0085","series-title":"LSD Psychotherapy","author":"Grof","year":"1980"},{"key":"10.1016\/j.jad.2025.120732_bb0090","doi-asserted-by":"crossref","first-page":"151","DOI":"10.1177\/02698811211073759","article-title":"Efficacy and safety of psilocybin-assisted treatment for major depressive disorder: prospective 12-month follow-up","volume":"36","author":"Gukasyan","year":"2022","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2025.120732_bb0095","doi-asserted-by":"crossref","first-page":"1771","DOI":"10.1002\/sim.791","article-title":"On tests of the overall treatment effect in meta-analysis with normally distributed responses","volume":"20","author":"Hartung","year":"2001","journal-title":"Stat. Med."},{"key":"10.1016\/j.jad.2025.120732_bb0100","doi-asserted-by":"crossref","first-page":"384","DOI":"10.1177\/0269881121992676","article-title":"Dose-response relationships of psilocybin-induced subjective experiences in humans","volume":"35","author":"Hirschfeld","year":"2021","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2025.120732_bb0105","doi-asserted-by":"crossref","first-page":"1602","DOI":"10.1038\/s41386-023-01588-2","article-title":"Dose-response relationships of LSD-induced subjective experiences in humans","volume":"48","author":"Hirschfeld","year":"2023","journal-title":"Neuropsychopharmacol"},{"key":"10.1016\/j.jad.2025.120732_bb0110","doi-asserted-by":"crossref","first-page":"215","DOI":"10.1016\/j.biopsych.2022.08.025","article-title":"Lysergic acid diethylamide-assisted therapy in patients with anxiety with and without a life-threatening illness: a randomized, double-blind, placebo-controlled phase II study","volume":"93","author":"Holze","year":"2023","journal-title":"Biol. Psychiatry"},{"key":"10.1016\/j.jad.2025.120732_bb0115","doi-asserted-by":"crossref","first-page":"362","DOI":"10.1192\/bjp.2024.99","article-title":"LSD-assisted therapy in patients with anxiety: open-label prospective 12-month follow-up","volume":"225","author":"Holze","year":"2024","journal-title":"Br. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.120732_bb0120","doi-asserted-by":"crossref","first-page":"747","DOI":"10.1037\/bul0000015","article-title":"The effects of cognitive behavioral therapy as an anti-depressive treatment is falling: a meta-analysis","volume":"141","author":"Johnsen","year":"2015","journal-title":"Psychol. Bull."},{"key":"10.1016\/j.jad.2025.120732_bb0125","doi-asserted-by":"crossref","first-page":"194","DOI":"10.1016\/j.jad.2022.09.168","article-title":"Psychedelic therapy for depressive symptoms: a systematic review and meta-analysis","volume":"322","author":"Ko","year":"2023","journal-title":"J. Affect. Disord."},{"key":"10.1016\/j.jad.2025.120732_bb0130","doi-asserted-by":"crossref","first-page":"20","DOI":"10.1177\/02698811211044688","article-title":"Assessing the effects of methodological differences on outcomes in the use of psychedelics in the treatment of anxiety and depressive disorders: a systematic review and meta-analysis","volume":"36","author":"Leger","year":"2022","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2025.120732_bb0135","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1016\/j.psc.2024.02.006","article-title":"Psychedelics and evidence-based psychotherapy: a systematic review with recommendations for advancing psychedelic therapy research","volume":"47","author":"Leone","year":"2024","journal-title":"Psychiatr. Clin. North Am."},{"key":"10.1016\/j.jad.2025.120732_bb0140","doi-asserted-by":"crossref","first-page":"258","DOI":"10.1016\/j.jpainsymman.2023.06.006","article-title":"HOPE: a pilot study of psilocybin enhanced group psychotherapy in patients with Cancer","volume":"66","author":"Lewis","year":"2023","journal-title":"J. Pain Symptom Manag."},{"key":"10.1016\/j.jad.2025.120732_bb0145","doi-asserted-by":"crossref","first-page":"289","DOI":"10.1080\/02791072.2020.1769878","article-title":"A Meta-analysis of placebo-controlled trials of psychedelic-assisted therapy","volume":"52","author":"Luoma","year":"2020","journal-title":"J. Psychoactive Drugs"},{"key":"10.1016\/j.jad.2025.120732_bb9000","doi-asserted-by":"crossref","first-page":"1721","DOI":"10.3389\/fpsyg.2018.01721","article-title":"More realistic forecasting of future life events after psilocybin for treatment-resistant depression","volume":"9","author":"Lyons","year":"2018","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2025.120732_bb0150","doi-asserted-by":"crossref","first-page":"264","DOI":"10.1124\/pr.115.011478","article-title":"Psychedelics","volume":"68","author":"Nichols","year":"2016","journal-title":"Pharmacol. Rev."},{"key":"10.1016\/j.jad.2025.120732_bb0155","doi-asserted-by":"crossref","first-page":"208","DOI":"10.1002\/embr.201338282","article-title":"Mind-altering drugs and research: From presumptive prejudice to a Neuroscientific Enlightenment?: Science & Society series on \u201cDrugs and Science\u201d","volume":"15","author":"Nutt","year":"2014","journal-title":"EMBO Rep."},{"key":"10.1016\/j.jad.2025.120732_bb0160","article-title":"PRISMA 2020 explanation and elaboration: updated guidance and exemplars for reporting systematic reviews","volume":"372","author":"Page","year":"2021","journal-title":"BMJ"},{"key":"10.1016\/j.jad.2025.120732_bb0165","article-title":"Lower-dose psycholytic therapy \u2013 a neglected approach","volume":"13","author":"Passie","year":"2022","journal-title":"Front. Psych."},{"key":"10.1016\/j.jad.2025.120732_bb0170","author":"R Core Team"},{"key":"10.1016\/j.jad.2025.120732_bb0175","doi-asserted-by":"crossref","first-page":"843","DOI":"10.1001\/jama.2023.14530","article-title":"Single-dose psilocybin treatment for major depressive disorder: a randomized clinical trial","volume":"330","author":"Raison","year":"2023","journal-title":"JAMA"},{"key":"10.1016\/j.jad.2025.120732_bb0180","doi-asserted-by":"crossref","first-page":"391","DOI":"10.1176\/appi.ajp.2019.19010035","article-title":"Psychedelics and psychedelic-assisted psychotherapy","volume":"177","author":"Reiff","year":"2020","journal-title":"Am. J. Psychiatry"},{"key":"10.1016\/j.jad.2025.120732_bb0185","doi-asserted-by":"crossref","first-page":"1079","DOI":"10.1177\/0269881120919957","article-title":"Efficacy of psychedelic treatments on depressive symptoms: a meta-analysis","volume":"34","author":"Romeo","year":"2020","journal-title":"J. Psychopharmacol. (Oxf.)"},{"issue":"3","key":"10.1016\/j.jad.2025.120732_bb0190","doi-asserted-by":"crossref","first-page":"190","DOI":"10.1016\/j.medj.2024.01.005","article-title":"Psilocybin-assisted psychotherapy for treatment resistant depression: a randomized clinical trial evaluating repeated doses of psilocybin","volume":"5","author":"Rosenblat","year":"2024","journal-title":"Med"},{"key":"10.1016\/j.jad.2025.120732_bb0195","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1177\/0269881116675512","article-title":"Rapid and sustained symptom reduction following psilocybin treatment for anxiety and depression in patients with life-threatening cancer: a randomized controlled trial","volume":"30","author":"Ross","year":"2016","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2025.120732_bb0200","doi-asserted-by":"crossref","first-page":"671","DOI":"10.1038\/nmeth.2089","article-title":"NIH image to ImageJ: 25 years of image analysis","volume":"9","author":"Schneider","year":"2012","journal-title":"Nat. Methods"},{"key":"10.1016\/j.jad.2025.120732_bb0205","doi-asserted-by":"crossref","first-page":"364","DOI":"10.1016\/j.jpsychires.2023.03.031","article-title":"Pilot study of single-dose psilocybin for serotonin reuptake inhibitor-resistant body dysmorphic disorder","volume":"161","author":"Schneier","year":"2023","journal-title":"J. Psychiatr. Res."},{"key":"10.1016\/j.jad.2025.120732_bb0210","doi-asserted-by":"crossref","first-page":"698","DOI":"10.1177\/02698811231154852","article-title":"Psilocybin-assisted therapy for major depressive disorder: an exploratory placebo-controlled, fixed-order trial","volume":"37","author":"Sloshower","year":"2023","journal-title":"J. Psychopharmacol. (Oxf.)"},{"key":"10.1016\/j.jad.2025.120732_bb0215","doi-asserted-by":"crossref","first-page":"1101","DOI":"10.1007\/s00213-024-06598-6","article-title":"In the new era of psychedelic assisted therapy: a systematic review of study methodology in randomized controlled trials","volume":"241","author":"Soliman","year":"2024","journal-title":"Psychopharmacology"},{"key":"10.1016\/j.jad.2025.120732_bb0220","article-title":"ROBINS-I: a tool for assessing risk of bias in non-randomised studies of interventions","volume":"355","author":"Sterne","year":"2016","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1016\/j.jad.2025.120732_bb0225","article-title":"RoB 2: a revised tool for assessing risk of bias in randomised trials","volume":"366","author":"Sterne","year":"2019","journal-title":"BMJ (Clinical Research Ed.)"},{"key":"10.1016\/j.jad.2025.120732_bb0230","doi-asserted-by":"crossref","DOI":"10.1177\/20451253231198466","article-title":"History repeating: guidelines to address common problems in psychedelic science","volume":"13","author":"van Elk","year":"2023","journal-title":"Ther. Adv. Psychopharmacol."},{"key":"10.1016\/j.jad.2025.120732_bb0235","doi-asserted-by":"crossref","DOI":"10.1016\/j.neubiorev.2022.104793","article-title":"Pharmacological, neural, and psychological mechanisms underlying psychedelics: a critical review","volume":"140","author":"van Elk","year":"2022","journal-title":"Neurosci. Biobehav. Rev."},{"key":"10.1016\/j.jad.2025.120732_bb0240","doi-asserted-by":"crossref","first-page":"1","DOI":"10.18637\/jss.v036.i03","article-title":"Conducting meta-analyses in R with the metafor package","volume":"36","author":"Viechtbauer","year":"2010","journal-title":"J. Stat. Softw."},{"key":"10.1016\/j.jad.2025.120732_bb0245","doi-asserted-by":"crossref","first-page":"611","DOI":"10.1038\/s41583-020-0367-2","article-title":"Psychedelic drugs: neurobiology and potential for treatment of psychiatric disorders","volume":"21","author":"Vollenweider","year":"2020","journal-title":"Nat. Rev. Neurosci."},{"key":"10.1016\/j.jad.2025.120732_bb0250","article-title":"Single-dose psilocybin-assisted therapy in major depressive disorder: a placebo-controlled, double-blind, randomised clinical trial","volume":"56","author":"von Rotz","year":"2023","journal-title":"EClinicalMedicine"},{"key":"10.1016\/j.jad.2025.120732_bb0255","doi-asserted-by":"crossref","DOI":"10.3389\/fpsyg.2022.873279","article-title":"Psychedelics and psychotherapy: cognitive-behavioral approaches as default","volume":"13","author":"Yaden","year":"2022","journal-title":"Front. Psychol."},{"key":"10.1016\/j.jad.2025.120732_bb0260","doi-asserted-by":"crossref","DOI":"10.1016\/j.psychres.2024.115886","article-title":"Efficacy and safety of psychedelics for the treatment of mental disorders: a systematic review and meta-analysis","volume":"335","author":"Yao","year":"2024","journal-title":"Psychiatry Res."},{"key":"10.1016\/j.jad.2025.120732_bb0265","doi-asserted-by":"crossref","first-page":"938","DOI":"10.3390\/jcm11040938","article-title":"Trajectory of antidepressant effects after single- or two-dose Administration of Psilocybin: a systematic review and multivariate Meta-analysis","volume":"11","author":"Yu","year":"2022","journal-title":"J. Clin. Med."}],"container-title":["Journal of Affective Disorders"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725021743?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0165032725021743?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,12,11]],"date-time":"2025-12-11T03:47:13Z","timestamp":1765424833000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0165032725021743"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,2]]},"references-count":54,"alternative-id":["S0165032725021743"],"URL":"https:\/\/doi.org\/10.1016\/j.jad.2025.120732","relation":{},"ISSN":["0165-0327"],"issn-type":[{"value":"0165-0327","type":"print"}],"subject":[],"published":{"date-parts":[[2026,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Does number of dosing sessions and type of adjunctive psychotherapy affect outcomes in psychedelic-assisted-psychotherapy for depressive disorders and anxiety disorders? A systematic review and meta-analysis","name":"articletitle","label":"Article Title"},{"value":"Journal of Affective Disorders","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.jad.2025.120732","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2025 The Authors. Published by Elsevier B.V.","name":"copyright","label":"Copyright"}],"article-number":"120732"}}